Mark S Segal, MD, PhD - Research

Research at a glance

Top areas of exploration

Cells, Cultured , 19 publications
Biomarkers , 17 publications
Kidney Failure, Chronic , 16 publications
Hypertension , 16 publications

Research activity

161 publications

10,466 citations

Why is this important?

Active clinical trials

HyperQure RDN System

HQ-HTN-G01 is a prospective, multicenter, single arm, open label, early feasibility study to evaluate initial safety and device design concept of "HyperQureTM RDN System", laparoscopic renal denervation therapy, in patients with resistant鈥�

Investigator: Mark S Segal
Status: Accepting Candidates
Ages: 22 Years - 80 Years
Sexes: All

EASi-KIDNEY

Investigator: Mark S Segal
Status: Accepting Candidates

REGEN-006

The purpose of this study is to assess the safety and efficacy (including durability) of up to 2 REACT injections given 3 months (+30 days) apart and delivered percutaneously into biopsied and non-biopsied contralateral kidneys in participants with鈥�

Investigator: Mark S Segal
Status: Accepting Candidates
Ages: 30 Years - 80 Years
Sexes: All

My publications

161 publications

2020

Tubular Biomarkers and Chronic Kidney Disease Progression in SPRINT Participants.

American journal of nephrology

鈥�

2019

Antihypertensive therapy prescribing patterns and correlates of blood pressure control among hypertensive patients with chronic kidney disease.

Journal of clinical hypertension (Greenwich, Conn.)

鈥�

2019

Increased Preeclampsia Risk and Reduced Aortic Compliance With In Vitro Fertilization Cycles in the Absence of a Corpus Luteum.

Hypertension (Dallas, Tex. : 1979)

鈥�

2019

Integrating Point-of-Care Ultrasonography Into Nephrology Fellowship Training: A Model Curriculum.

American journal of kidney diseases : the official journal of the National Kidney Foundation

鈥�

2019

Maternal Cardiovascular Dysregulation During Early Pregnancy After In Vitro Fertilization Cycles in the Absence of a Corpus Luteum.

Hypertension (Dallas, Tex. : 1979)

鈥�

网红黑料